Table 1 Summary of the immunohistochemical analysis of nuclear YAP1 and TAZ expression in tumors of soft tissue and bone.
From: Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
Type | n | YAP1 | TAZ |
|---|---|---|---|
Angiosarcoma (AS) | 29 | 7 (24%) | 16 (55%) |
Ewing sarcoma (EwS) | 20 | 4 (20%) | 3 (15%) |
Leiomyosarcoma (LMS) | 68 | 30 (44%) | 5 (7%) |
Malignant peripheral nerve sheath tumor (MPNST) | 45 | 26 (58%) | 32 (71%) |
Solitary fibrous tumor (SFT) | 36 | 15 (42%) | 3 (8%) |
Synovial sarcoma (SySa) | 65 | 51 (78%) | 22 (34%) |
Well-differentiated liposarcoma (WDLS) | 55 | 21 (38%) | 3 (5%) |
Dedifferentiated liposarcoma (DDLS) | 74 | 24 (32%) | 23 (31%) |
Myxoid liposarcoma (MLS) | 85 | 77 (91%) | 47 (55%) |
Pleomorphic liposarcoma (PLS) | 9 | 3 (33%) | 4 (44%) |
Total | 486 | 258 (53%) | 158 (33%) |
